drugset / Trial / NCT02089438

DPP-4 Inhibition, Incretins and Islet Function

NCT02089438

Phase 4 Completed 24 enrolled Lund University
RandomizedParallel-groupOpen-labelBasic science

Summary

Hypothesis is that DPP-4 inhibition affects glucose levels through changes in incretin and islet hormones. The study examines this in relation to breakfast, lunch and dinner over an entire 24h study period by the use of three different DPP-4 inhibitors and placebo.

Timeline

Start
2014-05
Primary completion
2017-06
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg
Subject Sitagliptin Small molecule 100 mg
Subject Vildagliptin Other / unclassified 50 mg